An early look at selective RET inhibitor resistance: new challenges and opportunities
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An early look at selective RET inhibitor resistance: new challenges and opportunities
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-23
DOI
10.1038/s41416-021-01344-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
- (2021) J. Gainor et al. Journal of Thoracic Oncology
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
- (2020) Benjamin J. Solomon et al. Journal of Thoracic Oncology
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
- (2020) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.
- (2020) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
- (2020) Viola W. Zhu et al. Journal of Thoracic Oncology
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
- (2020) J.J. Lin et al. ANNALS OF ONCOLOGY
- Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
- (2020) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started